University of Toronto, Toronto, Canada; and.
Department of Ophthalmology, Tel Aviv Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Cornea. 2021 Oct 1;40(10):1282-1289. doi: 10.1097/ICO.0000000000002585.
To compare 4-year survival outcomes of Descemet membrane endothelial keratoplasty (DMEK) and Descemet-stripping automated endothelial keratoplasty (DSAEK) in eyes with previous glaucoma surgery.
This is a retrospective, comparative case series, including patients with previous trabeculectomy or glaucoma drainage device implantation, who later underwent either DMEK (n = 48) or DSAEK (n = 41). Follow-up was limited to 12 to 60 months to prevent bias. Primary outcomes were graft survival and rejection. Secondary outcomes were best spectacle-corrected visual acuity (BSCVA), detachment/rebubble, endothelial cell loss, and intraocular pressure elevations.
Baseline characteristics, follow-up duration, and preexisting glaucoma parameters did not differ significantly between the groups. Graft survival probability after DMEK and DSAEK was 75% and 75% at 1 year, 63% and 50% at 2 years, 49% and 44% at 3 years, 28% and 33% at 4 years, and 28% and 29% at 5 years, respectively (P = 0.899 between the groups). Graft rejection rates were 20.8% and 19.5%, respectively (P = 1.000). Primary failure, rebubbling, endothelial cell loss, and intraocular pressure elevation did not differ significantly between the groups. Preoperative BSCVA did not differ between the groups (P = 0.821). Postoperative BSCVA was significantly better in the DMEK group at 6, 12, and 24 months (P < 0.001, P = 0.022, and P = 0.047, respectively). In a multivariable model (R2 = 0.576), the type of surgery was the only significant factor affecting postoperative BSCVA, in favor of DMEK (coefficient value -0.518, P = 0.002).
In eyes with previous glaucoma surgery, DMEK and DSAEK had comparably low survival and comparably high rejection rates. Postoperative visual acuity might be better after DMEK in this setting.
比较有既往青光眼手术史的患者行后弹力膜内皮角膜移植术(DMEK)和撕囊联合内界膜移植术(DSAEK)的 4 年生存率。
这是一项回顾性、对比性病例系列研究,纳入了既往行小梁切除术或青光眼引流装置植入术且之后行 DMEK(n=48 例)或 DSAEK(n=41 例)的患者。为避免偏倚,随访时间限制在 12 至 60 个月。主要结局是移植物存活率和排斥反应。次要结局是最佳矫正视力(BSCVA)、脱离/再气泡、内皮细胞丢失和眼内压升高。
DMEK 和 DSAEK 组间的基线特征、随访时间和术前青光眼参数无显著差异。DMEK 和 DSAEK 术后 1 年的移植物存活率分别为 75%和 75%,2 年分别为 63%和 50%,3 年分别为 49%和 44%,4 年分别为 28%和 33%,5 年分别为 28%和 29%(两组间 P=0.899)。排斥反应发生率分别为 20.8%和 19.5%(P=1.000)。主要失败、再气泡、内皮细胞丢失和眼内压升高在两组间无显著差异。术前 BSCVA 两组间无差异(P=0.821)。术后 6、12 和 24 个月 DMEK 组的 BSCVA 显著提高(P<0.001、P=0.022 和 P=0.047)。在多变量模型(R2=0.576)中,手术类型是唯一显著影响术后 BSCVA 的因素,DMEK 更为有利(系数值-0.518,P=0.002)。
在有既往青光眼手术史的患者中,DMEK 和 DSAEK 的存活率较低,排斥反应率较高。在这种情况下,DMEK 术后视力可能更好。